Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
General good health, other than perennial allergic rhinitis
History and diagnosis of perennial allergic rhinitis by skin prick
Normal body weight as defined by the study protocol
You may not be if
Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days following the study period
Participation in any investigational drug trial within the 30 days preceding the Screening Visit
A known hypersensitivity to any corticosteroid or any of the excipients in the formulations
Use of any prohibited concomitant medications as defined by the study protocol
Previous participation in an intranasal ciclesonide study
Non-vaccinated exposure to or active infection with, chickenpox or measles within the 21 days preceding the Screening Visit
Clareo Health | Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)
